REGENXBIO Inc.
RGNX
$7.77
$0.010.13%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 170.44M | 161.32M | 155.78M | 156.72M | 83.33M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 170.44M | 161.32M | 155.78M | 156.72M | 83.33M |
| Cost of Revenue | 248.60M | 239.76M | 244.75M | 239.49M | 242.09M |
| Gross Profit | -78.16M | -78.44M | -88.96M | -82.77M | -158.76M |
| SG&A Expenses | 82.86M | 75.53M | 74.70M | 73.68M | 71.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 179.00K | 958.00K | 930.00K | 914.00K | 865.00K |
| Total Operating Expenses | 331.64M | 316.25M | 320.38M | 314.07M | 314.57M |
| Operating Income | -161.20M | -154.93M | -164.60M | -157.36M | -231.25M |
| Income Before Tax | -193.88M | -177.92M | -175.57M | -157.69M | -227.10M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -193.88 | -177.92 | -175.57 | -157.69 | -227.10 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -193.88M | -177.92M | -175.57M | -157.69M | -227.10M |
| EBIT | -161.20M | -154.93M | -164.60M | -157.36M | -231.25M |
| EBITDA | -145.58M | -139.16M | -148.75M | -141.37M | -215.03M |
| EPS Basic | -3.75 | -3.46 | -3.44 | -3.11 | -4.61 |
| Normalized Basic EPS | -2.35 | -2.16 | -2.15 | -1.94 | -2.85 |
| EPS Diluted | -3.75 | -3.46 | -3.44 | -3.11 | -4.61 |
| Normalized Diluted EPS | -2.35 | -2.16 | -2.15 | -1.94 | -2.85 |
| Average Basic Shares Outstanding | 206.29M | 205.41M | 204.52M | 203.63M | 198.01M |
| Average Diluted Shares Outstanding | 206.36M | 205.48M | 204.59M | 203.71M | 198.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |